Allogene Therapeutics’ (ALLO) Buy Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note published on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a $14.00 price target on the stock. Several other analysts also recently issued reports on ALLO. William Blair reissued an “outperform” rating on shares of […]
Canaccord Genuity Group reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note published on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a $14.00 price target on the stock. Several other analysts also recently issued reports on ALLO. William Blair reissued an “outperform” rating on shares of […]
